Drug Profile
Duvoglustat - Amicus Therapeutics
Alternative Names: 1-deoxynojirimycin hydrochloride; AT-2220; AT2220-ERT combo therapy; AT2220-IV; Duvoglustat HCl; duvoglustat hydrochloride; duvoglustat-ERT combo therapy; HGT-3510Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Amicus Therapeutics
- Class Alkaloids; Imino pyranoses; Pharmacological chaperones; Small molecules
- Mechanism of Action Alpha-glucosidase stimulants; Protein folding stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Glycogen storage disease type II
Most Recent Events
- 09 Aug 2015 Clinical development of duvoglustat is ongoing
- 14 Feb 2013 Amicus Therapeutics plans a repeat-dose trial for Glycogen storage disease type II (IV formulation) in USA
- 04 Jan 2013 Interim data from a phase II trial in Glycogen storage disease type II (combination with ERT) released by Amicus Therapeutics